# Tesofensine

Source: https://aminodesk.com/library/tesofensine
Publisher: Amino Desk
Updated: 2026-11-17
Clinical review: pending

Tesofensine is a pill that suppresses appetite by acting on three brain chemicals. It is not a peptide. A mid-stage trial showed strong weight loss, and the same trial showed the problem that has kept it from approval: it raises heart rate and blood pressure.

- **Legal lane:** not FDA-approved. No prescription product exists in the US.
- **Evidence grade:** B. One good mid-stage trial, no completed US program.
- **Form:** capsule by mouth, once a day
- **Type:** triple monoamine reuptake inhibitor, not a peptide

## What it is

Tesofensine blocks the reuptake of serotonin, noradrenaline and dopamine. It was first developed for Parkinson's and Alzheimer's disease, where it did not work. Weight loss in those trials led to its being tested for obesity.

## What the evidence shows

The main evidence is one Phase 2 trial published in The Lancet in 2008. It followed 203 adults with obesity at five Danish centers for 24 weeks, testing 0.25 mg, 0.5 mg and 1 mg a day against placebo. At 0.5 mg, average weight loss was 9.2%, against 2.0% on placebo. That was about double what the weight-loss drugs of the time achieved.

The 1 mg dose produced more weight loss and more side effects. A later program in Mexico, reported as 372 patients, broadly matched the weight loss. No large trial has tested heart outcomes.

## Legal status

- Not FDA-approved, and no US Phase 3 program was running when we checked.
- Reports on its status in Mexico conflict. Some say it was approved there in 2023; a more recent summary says approval was still being pursued. We could not settle this from a primary source.
- Some US sellers and pharmacies have marketed it. No approved product stands behind those sales.

## Reported dosing

**No approved dose exists in the US.**

The Phase 2 trial tested 0.25 mg, 0.5 mg and 1 mg once a day, and later work continued with 0.5 mg. Those are trial doses in monitored studies, not a recommendation. The drug stays in the body a long time, with a half-life reported at about nine days, so its effects persist for weeks after stopping.

## Safety

- **Heart rate and blood pressure:** both rose in a dose-dependent way. This is the main safety concern, and the same mechanism drives the weight loss.
- **Common effects:** dry mouth, insomnia, constipation and mood changes.
- **Long-term safety:** not established. There is no heart-outcomes trial.
- Anyone with heart disease, high blood pressure or a mood disorder has specific reasons for caution.

## Common questions

### Is tesofensine a peptide?

No. It is a small-molecule drug taken as a capsule.

### How much weight did people lose on tesofensine?

In the main trial, 9.2% of body weight over 24 weeks at 0.5 mg a day, against 2.0% on placebo.

### Is tesofensine FDA-approved?

No. There is no approved product in the US.

### Why was it not approved?

It raises heart rate and blood pressure, and no large trial has tested its effect on heart outcomes.

## Sources

- [Astrup et al., 2008: tesofensine Phase 2 trial, The Lancet (PubMed)](https://pubmed.ncbi.nlm.nih.gov/18950853/)
- [Superpower: tesofensine regulatory status as of September 2026](https://superpower.com/guides/peptide-science/tesofensine)
- [Superpower: an earlier summary reporting Mexican approval in 2023](https://superpower.com/guides/peptides/tesofensine)
- [TrimRx: review of the tesofensine trials, including the Mexican program (a seller's article)](https://trimrx.com/blog/?p=107159)
- [FormBlends: trial size, half-life and status (a seller's article)](https://www.formblends.com/peptides/tesofensine)

---
Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL.
